HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET

Company Participants

David Ng - Head:Investor Relations
Wei-Guo Su - Chief Executive Officer & Chief Scientific Officer
Johnny Cheng - Chief Financial Officer
George Yuan - Head of Commercial
Michael Shi - Executive Vice President, Head of R&D & Chief Medical Officer

Conference Call Participants

Alec Stranahan - Bank of America
Chen Chen - UBS
Clara Dong - Jefferies
Adam McCarter - Cavendish
Paul Choi - Goldman Sachs
Julie Simmonds - Panmure Liberum

David Ng

Hello, everyone. Welcome to HUTCHMED 2014 Interim Results Presentation. My name is David Ng is Head of HUTCHMED IR. Our results announcement as well as our presentation slides have already been uploaded to our company homepage as well as the Hong Kong Stock Exchange website.

Before we start just a few quick reminder, all audiences are currently muted during the presentation by our management, and then we will followed by a Q&A session. Second, please type your name as well as your company name to show up on your screen.

And finally please read on page 2 of our presentation slides for the safe harbor statement and disclaimer. The performance and results of operation of the HUTCHMED contained within this presentation are historical in nature and past performance is no guarantee of future results.

So without further delay, let me introduce our Chief Executive Officer and Chief Scientific Officer Dr. Su to begin our presentation. Okay Dr. Su?

Wei-Guo Su

Thanks David. Good evening good morning everyone. Welcome to HUTCHMED First Half 2024 Results Conference Call. With the today are Johnny Cheng, CFO; George Yuan, Head of Commercial. George joined us month ago. George is a highly experienced veteran in oncology product sales and marketing. He joined us from Merck, where he had its China commercial operations for the last seven years with great success. And George will be followed by Mike who will give a brief update on the pipeline.

Next slide please. Slide number 4. Just to give you a quick summary first half of 2024. We continue to execute on our strategy towards self-sustaining. As a big part of this strategy is globalization. We are launching fruquintinib worldwide with our partner Takeda and we look forward to filing for approval for our second product savolitinib in the US later this year with our partner AstraZeneca.

On the pipeline, we continue to file for life cycle indications for the first wave of products. At the same time, the second wave product planet tazemetostat NDAs are under review in China and we expect to launch them in the next 6 to 12 months. Our best-in-class IDH12 inhibitor HMPL-306 entered into Phase III in recurrent and refractory AML.